Announcements Trials
Browse Landscape

Phase

Phase 1 2Phase 4 1

Status

Completed 3

Sponsor Class

INDUSTRY 2NIH 1

Study Type

Interventional 3

Sponsor

Cancer Type

Other solid neoplasm 3

Conditions

Breast Neoplasms 300Carcinoma, Non-Small-Cell Lung 225Neoplasms 195Prostatic Neoplasms 164Multiple Myeloma 139Neoplasm Metastasis 117Melanoma 113Colorectal Neoplasms 108Leukemia, Myeloid, Acute 107Lung Neoplasms 98Lymphoma 97Ovarian Neoplasms 87Squamous Cell Carcinoma of Head and Neck 77Lymphoma, Non-Hodgkin 73Leukemia, Lymphocytic, Chronic, B-Cell 72Myelodysplastic Syndromes 65Triple Negative Breast Neoplasms 64Pancreatic Neoplasms 64Hematologic Neoplasms 60Parkinson Disease 4, Autosomal Dominant Lewy Body 59Head and Neck Neoplasms 59Glioblastoma 58Precursor Cell Lymphoblastic Leukemia-Lymphoma 57Recurrence 56Leukemia 56Sarcoma 50Brain Neoplasms 50Lymphoma, Large B-Cell, Diffuse 48Carcinoma, Hepatocellular 47Lymphoma, Follicular 46

Interventions

sacituzumab govitecan 1bintrafusp alfa protein, human 1Tomography, X-Ray Computed 1Nivolumab 1Ipilimumab 1Electrocardiography 1Echocardiography 1

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

3 trials
RecentStart dateEnrollment
Has results × Metastatic Solid Tumors × 1 year × Clear all
NCT04457778 2026-05-04

First in Human Study of M6223

EMD Serono

Phase 1 Completed
58 enrolled 38 charts
Other solid neoplasm

Metastatic Solid Tumors

NCT03388632 2025-12-18

Recombinant Interleukin-15 in Combination With Checkpoint Inhibitors Nivolumab and Ipilimumab in People With Refractory Cancers

National Institutes of Health Clinical Center (CC)

Phase 1 Completed
31 enrolled 20 charts
Other solid neoplasm

Metastatic Solid Tumors

NCT04319198 2025-09-30

Rollover Study in Participants With Metastatic Solid Tumors Benefiting From Therapy With Sacituzumab Govitecan-hziy

Gilead Sciences

Phase 4 Completed
25 enrolled 15 charts
Other solid neoplasm

Metastatic Solid Tumors

Data powered by HemOnc (CC BY 4.0) Colophon âš¡